UBIO:NSD-Proshares UltraPro Nasdaq Biotechnology

ETF | Trading--Leveraged Equity | NASDAQ Global Market

Last Closing

USD 29.4

Change

+0.66 (+2.30)%

Market Cap

USD 0.04B

Volume

0.08M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the NASDAQ Biotechnology Index? (the "index"). The fund invests in securities and derivatives that the advisor believes, should have similar daily return characteristics as three times the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.

Inception Date: 22/06/2015

Primary Benchmark: NASDAQ Biotechnology TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.36%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-18 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Mer Price(Change) Market Cap
TQQQ ProShares UltraPro QQQ 0.95 %

+0.54 (+0.88%)

USD 22.36B
BIB ProShares Ultra Nasdaq Biotech.. 0.95 %

+1.78 (+3.16%)

USD 0.10B

ETFs Containing UBIO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 47.00% 100% F 96% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 47.00% 100% F 96% N/A
Trailing 12 Months  
Capital Gain -22.28% 33% F 33% F
Dividend Return N/A N/A N/A N/A F
Total Return -22.28% 33% F 31% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 0.26% 33% F 36% F
Dividend Return 0.26% 33% F 30% F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 33.62% 100% F 37% F
Risk Adjusted Return 0.76% 33% F 30% F
Market Capitalization 0.04B 33% F 16% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.